Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.

Author(s): Poveda E, Anta L, Blanco JL, Casado JL, Gutierrez F, Garcia F, Gomez-Sirvent JL, Iribarren JA, Soriano V, de Mendoza C, Resistance Platform of the Spanish AIDS Research Network (ResRIS)

Affiliation(s): Infectious Diseases Department, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain. evapoveda@hotmail.com

Publication date & source: 2010-07, Antimicrob Agents Chemother., 54(7):3018-20. Epub 2010 May 17.

Publication type: Research Support, Non-U.S. Gov't

The presence of resistance mutations in patients failing tipranavir or darunavir was examined at the national drug resistance database of the Spanish AIDS Research Network. Although mutations emerging during tipranavir and darunavir failures differed considerably, cross-resistance was found in up to half of the patients tested. Interestingly, mutation 54L, which is associated with tipranavir hypersusceptibility, was selected in half of the darunavir failures. Thus, resistance testing seems mandatory to ensure the benefit of the sequential use of these drugs.